ADDF

October 27, 2017

Two Alzheimer’s Organizations to Fund Phase 2 Trial of Amylyx Combo Therapy

News

The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation will fund a Phase 2 clinical trial of a combination therapy that Amylyx Pharmaceuticals is developing for Alzheimer’s disease. Amylyx will receive $1.85 million ... Read more

October 16, 2017

Alzheimer’s Nonprofit, Pfizer, Johns Hopkins Partnering on Therapy Development

News

The Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are supporting a Johns Hopkins University School of Medicine effort to develop therapies for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Valina Dawson, a ... Read more

July 6, 2017

AgeneBio Receives Grant for Drug-Discovery Program Targeting Cognitive Decline in Alzheimer’s

News

AgeneBio has received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of a novel GABAA discovery program targeting hippocampal overactivity in the brain, which ... Read more

April 26, 2017

Oryzon Getting $300,000 to Continue Developing Alzheimer’s Therapy ORY-2001

News

Oryzon Genomics is receiving $300,000 from the Alzheimer’s Drug Discovery Foundation to continue developing its Alzheimer’s treatment ORY-2001. In exchange, the foundation, which has been a longtime partner of Oryzon, will receive ... Read more

January 20, 2017

Alzheimer’s Scholar Program Seeks Proposals for Disease Research, Treatments

News

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Harrington Discovery Institute are calling for proposals for their 2017 ADDF-Harrington Scholar Award, which supports innovative research that aims to prevent, ... Read more

January 20, 2016May 17, 2016

Alzheimer’s Drug Researchers with ADDF Grants Gaining Access to New Services

News

PsychoGenics Inc. and the Alzheimer’s Drug Discovery Foundation (ADDF) announced a collaboration that opens PsychoGenics’ Alzheimer’s animal models and investigational services to recipients of ADDF grants who are working in preclinical Alzheimer’s ... Read more

September 12, 2014September 30, 2014

Alzheimer’s Drug Discovery Foundation, OnDeckBiotech to Launch Open Access Research Platform

Alzheimer's News, News

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Boston-based software company OnDeckBiotech are launching a new open access platform with the purpose of creating an improved way to connect scientists with a ... Read more

Pin It on Pinterest